Antibody response of 3-dose Covid vaccination schedule in immunocompromised patients with hematologic cancers

JAMA Network

About The Study: In this study that included 584 immunocompromised patients with hematologic cancers, a third Moderna COVID-19 vaccination was associated with significantly improved SARS-CoV-2 antibody concentrations comparable to those obtained by healthy individuals after the standard two-dose Moderna vaccination schedule.

Authors: Mette D. Hazenberg, M.D., Ph.D., of the University of Amsterdam, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link


/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.